Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends
Metabolites · 31.01.2024 · 14 (2) · 98
DOI: 10.3390/metabo14020098 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 31.01.2024. Verfasst von Fenna Sillé und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Alternatives to Animal Testing (CAAT), Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health and Wh…. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, NINDS NIH HHS, European Commission.
Abstract (Originalsprache)
Metabolomics is emerging as a powerful systems biology approach for improving preclinical drug safety assessment. This review discusses current applications and future trends of metabolomics in toxicology and drug development. Metabolomics can elucidate adverse outcome pathways by detecting endogenous biochemical alterations underlying toxicity mechanisms. Furthermore, metabolomics enables better characterization of human environmental exposures and their influence on disease pathogenesis. Metabolomics approaches are being increasingly incorporated into toxicology studies and safety pharmacology evaluations to gain mechanistic insights and identify early biomarkers of toxicity. However, realizing the full potential of metabolomics in regulatory decision making requires a robust demonstration of reliability through quality assurance practices, reference materials, and interlaboratory studies. Overall, metabolomics shows great promise in strengthening the mechanistic understanding of toxicity, enhancing routine safety screening, and transforming exposure and risk assessment paradigms. Integration of metabolomics with computational, in vitro, and personalized medicine innovations will shape future applications in predictive toxicology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Alternatives to Animal Testing (CAAT), Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health and Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 2…
- CAAT-Europe, University of Konstanz, Universitätsstraße 10, 78464 Konstanz, Germany.
ORCID-Profile: Thomas Hartung
Förderung
- NIEHS NIH HHS
- NINDS NIH HHS
- European Commission
- National Institute of Neurological disorders and stroke
- Johns Hopkins University 2022 Discovery Award
- Johns Hopkins University Exposome Collaborative
Zitieren
APA
Sillé, F., & Hartung, T. (2024). Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends. Metabolites, 14(2), 98. https://doi.org/10.3390/metabo14020098
Vancouver
Sillé F, Hartung T. Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends. Metabolites. 2024;14(2):98. doi:10.3390/metabo14020098
BibTeX
@article{Sill2024,
author = {Sillé, Fenna and Hartung, Thomas},
title = {Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends},
journal = {Metabolites},
year = {2024},
volume = {14},
number = {2},
pages = {98},
doi = {10.3390/metabo14020098}
}
EUVIMED